Neurocrine Biosciences director Lyons sells 15,000 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Neurocrine Biosciences Inc. director Gary A. Lyons exercised 15,000 non-qualified stock options at $53.64 per share, acquiring 15,000 common shares on November 17, 2026. He sold 15,000 common shares that day in four sale entries, with the dispositions effected by a broker under a Rule 10b5-1 trading plan.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option F7 | 15,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 15,000 | $53.64 | $805K |
| Sale | Common Stock F1, F2 | 1,200 | $163.1106 | $196K |
| Sale | Common Stock F1, F3 | 4,011 | $163.938 | $658K |
| Sale | Common Stock F1, F4 | 5,689 | $165.1547 | $940K |
| Sale | Common Stock F1, F5, F6 | 4,100 | $165.8968 | $680K |
Footnotes (7)
- F1. The dispositions reported in this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- F2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $162.45 to $163.42. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $163.49 to $164.43. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F4. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $164.57 to $165.56. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F5. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $165.57 to $166.06. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F6. 116,158 of the reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power.
- F7. The option was granted May 22, 2017 and vested in 12 equal monthly installments beginning June 22, 2017. These options are due to expire on May 22, 2027.
Key Figures
Key Terms
Non-Qualified Stock Option financial
Rule 10b5-1 trading plan regulatory
vested in 12 equal monthly installments financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many NBIX options did Gary A. Lyons exercise?
When was the trading plan used for Gary A. Lyons’s NBIX sale adopted?
AI-generated analysis. How Rhea-AI works. Not financial advice.